Genhouse Bio

Executive Summary

Genhouse Bio is a clinical-stage biotechnology company headquartered in Suzhou, China, dedicated to developing targeted oncology therapies with a focus on the Ras-MAPK signaling pathway and synthetic lethality mechanisms. Founded in 2020, the company has raised $42 million and built a pipeline of antibody-based candidates aimed at addressing high-unmet-need cancers. With a strong emphasis on global competitiveness, Genhouse Bio leverages deep expertise in cancer biology to advance novel treatments that could offer significant advantages over existing options. The company is currently in Phase 1 clinical development, positioning it to generate initial proof-of-concept data in the near term.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 clinical data readout for lead candidate40% success
• Q4 2026IND filing for second pipeline candidate70% success
• Q2 2026Strategic partnership or licensing deal for regional rights30% success